ERBB2 and breast carcinoma: Due to the importance of PI3K signaling, pharmacological inhibitors of the pathway have been developed as anti-neoplastic agents (41), culminating in the FDA approval of alpelisib for ER-positive, HER2-negative, PIK3CA-mutant breast cancer (42).